CAS 478149-53-0

N-(3R)-1-Azabicyclo[2.2.2]oct-3-ylfuro[2,3-c]pyridine-5-carboxamide

Description:

N-(3R)-1-Azabicyclo[2.2.2]oct-3-ylfuro[2,3-c]pyridine-5-carboxamide is a chemical compound characterized by its complex bicyclic structure, which includes a nitrogen atom in the bicyclic framework, contributing to its potential biological activity. The presence of a furo[2,3-c]pyridine moiety suggests that it may exhibit interesting pharmacological properties, possibly interacting with various biological targets. The carboxamide functional group enhances its solubility and may influence its binding affinity to receptors or enzymes. This compound is likely to be of interest in medicinal chemistry, particularly in the development of new therapeutic agents. Its stereochemistry, indicated by the (3R) designation, may also play a crucial role in its biological activity, as stereoisomers can exhibit significantly different effects in biological systems. Overall, this compound represents a unique scaffold that could be explored for its potential applications in drug discovery and development.

Formula: C₁₅H₁₇N₃O₂

InChI: InChI=1S/C15H17N3O2/c19-15(12-7-11-3-6-20-14(11)8-16-12)17-13-9-18-4-1-10(13)2-5-18/h3,6-8,10,13H,1-2,4-5,9H2,(H,17,19)/t13-/m0/s1

InChI key: InChIKey=IPKZCLGGYKRDES-ZDUSSCGKSA-N

SMILES: N(C(=O)C=1C=C2C(=CN1)OC=C2)[C@@H]3C4CCN(C3)CC4

Synonyms:

• N-(3R)-1-Azabicyclo[2.2.2]oct-3-ylfuro[2,3-c]pyridine-5-carboxamide
• Furo[2,3-c]pyridine-5-carboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-
• PHA 543613

PHA 543613

CAS: 478149-53-0

PHA 543613

Purity: ≥98%

Molecular weight: 271.31g/mol

Ref: 54-BUP12435

PHA-543613

CAS: 478149-53-0

Formula: C₁₅H₁₇N₃O₂

Molecular weight: 271.31

Ref: 7W-GL4687

PHA-543613

CAS: 478149-53-0

PHA-543613 is a cholinergic nicotinic agonist that has been shown to stimulate the release of acetylcholine and dopamine. It also has activity on the nicotinic acetylcholine receptor, with effects including locomotor activity and growth factor-β1 release. PHA-543613 has shown efficacy in animal models for chronic cough and is being evaluated in human clinical trials for the treatment of chronic obstructive pulmonary disease (COPD). The drug has been shown to have an adverse cardiac effect, which may be due to its ability to activate α7 nicotinic acetylcholine receptors. PHA-543613's mechanism of action may also involve its potential anti-inflammatory properties, since it appears to inhibit microglial activation following ischemia–reperfusion injury.

Formula: C₁₅H₁₇N₃O₂

Purity: Min. 95%

Molecular weight: 271.31 g/mol

Ref: 3D-DUA14953

PHA 543613

CAS: 478149-53-0

PHA 543613 is a specific agonist of α7 nAChR (Ki = 8.8 nM) and can be used in studies about the cognitive deficits of Alzheimer's disease and schizophrenia.

Formula: C₁₅H₁₇N₃O₂

Purity: 99.43% - 99.96%

Color and Shape: Solid

Molecular weight: 271.31

Ref: TM-T23145